Call for Abstracts EACR 2023 Congress

Deadline Abstract submission: **06 March 2023**

Abstracts can only be submitted online.

Abstract Regulations

With the submission of an abstract to the EACR 2023 Congress, the first author (presenting author):

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the congress.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published online by EACR on the Congress website as a PDF proceedings book and through the Congress App. EACR is not publishing abstracts in any Journal Supplement for this Congress. Submitted abstracts cannot be withdrawn after 09 May 2023.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
- Abstracts should be organised under the headings:
  - Introduction
  - Material and method
  - Results and discussion
  - Conclusion
- The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract)
• Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

• Supplementary data or appendices will not be accepted.

• Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black and converted to images and inserted as images.

Only the **submitting author** will receive a confirmation/abstract number by email from the EACR 2023 Customer Service Team within 48 hours of submission. This confirmation of abstract receipt is **NOT** a notice of acceptance.

For questions regarding the online submission process, please contact our support team via: eacr@newway-management.com

**Abstract Selection Process**

The Scientific Committee will make the selection of abstracts for oral and poster presentations by **06 April 2023**. The presenting author will receive an email with the result of the review and the Scientific Committee's decision on the abstract no later than **06 April 2023**. Depending on the selection of presentation format by the committee further instructions on how to prepare posters, or presentation to at Congress will be provided.

If a selected author cannot present, the presenting author should assign a replacement presenter to present the abstract.

The following presentation formats are applicable for EACR 2023 Congress:

1. **Oral presentation**: the abstract is selected for oral presentation in a main Congress symposium
2. **Poster**: abstracts that have been selected for presentation in a poster format. Posters are grouped by (main) topic and displayed during specific Poster Sessions. A formal Poster Defence Session will be scheduled.
3. **Poster in the Spotlight session**: in addition to a poster presentation as above a ‘mini oral’ presentation is given at a set time in the dedicated moderated Posters in the Spotlight Session in the Spotlight Area located in the poster & exhibition area.

**Please note that if the abstract is accepted for oral or poster presentation, the abstract will only be published in the Congress Abstract Publications, if one of the authors is a registered participant to EACR 2023 Congress and full payment has been received by the advised deadline.**

**If Congress registration has not occurred, the Abstract will not be included in the publications or visible on the Congress Abstract Publications nor will a poster board be made available.**
Abstract Submission

Abstract submission procedure
Abstracts must be submitted online by not later than 06 March 2023, via the EACR 2023 Congress website.

Please follow the instructions on the screen.

Please note:
- When finished with the online submission, please click the “FINAL SUBMISSION” button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click “SAVE AND CLOSE”. This button allows you to update your abstract before final submission.
- After clicking “SAVE AND CLOSE”, your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click “FINAL SUBMISSION”. If you have not FINAL SUBMITTED your abstract by the deadline of 06 March 2023 your abstract can not be accepted.
- Within 24 hours of submission, only the presenting author will receive a confirmation by email. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
- If you do not receive any confirmation, please contact eacr@newway-management.com.
- Submitting an abstract for EACR 2023 Congress does not constitute registration for the Congress. Abstract presenters must register to attend EACR 2023 by following the instructions for registration on the EACR 2023 website.

For questions regarding the online submission process, please contact: eacr@newway-management.com

Only abstracts submitted online can be accepted. Abstracts submitted on paper or as email attachment will unfortunately not be considered.
Topics for Abstract Submission

1. CANCER CELL BIOLOGY
   - Cell Proliferation/Cell Cycle
   - Cell Death / Autophagy
   - Oncogenes and Tumour Suppressor Genes
   - Metastases and EMT
   - Aging and Cancer
   - Senescence
   - Cancer Cell Metabolism
   - Cancer Initiating Cells / Cancer Stem Cells

2. CANCER GENOMICS
   - Genomic Alterations in Cancer
   - Functional Genomics
   - Genomic profiling of Tumours
   - Large-scale Approaches to Cancer Gene Discovery
   - Spatial and 3D Analysis of Tumours
   - oGenomes and Transcriptomes of Cancer at Single Cell Level

3. EPIGENETICS
   - DNA Methylation
   - Epigenetic changes as Molecular Markers of Cancer
   - Epigenomics
   - Histone Modification
   - Epigenetic Mechanisms and Gene Silencing
   - Chromatin Structure and Function

4. BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
   - Application of Bioinformatics to Cancer Biology
   - Artificial Intelligence and Machine Learning
   - New Algorithms and new Software for Data Analysis
   - Mathematical Modeling and Statistical Methods
   - Molecular Modeling
   - Database Resources and Network Biology
   - Omics Technologies
   - Digital Clinical Trials

5. TUMOUR EVOLUTION AND HETEROGENEITY
   - Causes and Consequences of Tumour Heterogeneity
   - Methods to measure Tumour Evolution and Heterogeneity
   - Drug Resistance and Clonal Evolution
6. **DRUG RESISTANCE**  
   Novel Mechanisms  
   Regulation of Gene Expression in Drug Resistance  
   Reversal of Drug Resistance  
   Drug Transport and Metabolism  
   Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7. **BIOMARKERS IN TISSUE AND BLOOD**  
   Liquid Biopsies: Circulating DNA  
   Liquid Biopsies: Circulating Tumour Cells  
   Diagnostic Biomarkers  
   Prognostic Biomarkers  
   Biomarkers Predictive of Therapeutic Benefit  
   Early Detection Biomarkers

8. **SIGNALING PATHWAYS**  
   Receptors and Signal Transduction  
   Gene Expression, Transcriptional Regulation  
   Systems Biology  
   Intracellular Networks  
   Computational Models of Biological Systems

9. **CARCINOGENESIS**  
   Mutagenesis, Carcinogen Metabolism  
   Promotion and Progression  
   DNA Damage and Repair  
   Viral Oncogenesis

10. **TRANSLATIONAL RESEARCH**  
    Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment  
    Molecular Pathology  
    Imaging  
    Clinical Phase I/II trials with Targeted Drugs and Novel Agents  
    Bioinformatics in Therapies and Clinical Trials  
    Infrastructures (Biobanks, Databases, Genomic Resources, others)  
    Nanotechnologies in Cancer Research

11. **EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS**  
    Drug Discovery / Drug Design  
    Novel Targets, Delivery Systems  
    Mechanisms of Drug Action, Drug Profiling  
    New Therapies  
    Pharmacogenetics and Therapeutic Response  
    Pharmacogenomics  
    Pharmacokinetics
12. **TUMOUR IMMUNOLOGY**
   - Tumour Immunology
   - Immune Suppression and Escape
   - Tumour Antigens and Immune Effectors
   - Oncogenic Pathway-mediated Deregulation of Tumour Immunity
   - Antigen Processing and Presentation
   - Microbiome and Cancer

13. **IMMUNOTHERAPY**
   - Adoptive Cell Therapy
   - Immune Response to Therapies
   - Immunomodulatory Agents and Interventions
   - Therapeutic Antibodies, including Engineered Antibodies
   - Vaccines
   - Immune Checkpoints
   - Immune Mechanisms invoked by other Therapies including CARs

14. **RADIOBIOLOGY / RADIATION ONCOLOGY**
   - Tumour Cell Sensitisation to Radiotherapy
   - Radiation-activated Signaling Pathways
   - Cell Cycle and Apoptosis in Radiation Responses
   - Radiation Oncology; Preclinical and Clinical
   - Translational Radiation Research

15. **MOLECULAR AND GENETIC EPIDEMIOLOGY**
   - Risk Factors
   - Risk Assessment
   - Susceptibility Genes
   - Genotype / Phenotype Correlations
   - Genetic Polymorphisms and Cancer Susceptibility
   - Epidemiology

16. **PREVENTION and EARLY DETECTION**
   - Preclinical Prevention Studies, Markers and Prevention
   - Clinical Prevention Studies
   - Vaccination Against Cancer
   - Risk Factors: Heritable and Lifestyle related Risk Factors

17. **TUMOUR BIOLOGY**
   - Animal Models of Cancer
   - Genetic and Genomic Instability
   - Tumour Progression: Invasion and Metastasis
   - Tumour Microenvironment
Tumour Angiogenesis
Tumour Inflammation
RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response
Cell Competition
Tumour Dormancy and Persister Cells